Le Club suisse de la presse – Geneva Press Club a pour mission d’accueillir et d’aider les journalistes de passage à Genève et de favoriser les échanges entre les milieux suisses et internationaux de l’économie, de la politique, de la culture et des sciences d’une part, et de la presse suisse et étrangère installée en suisse romande et en France voisine d’autre part.

logo_press_club

Technical Briefing for the Launch of Pyramax®

Le 20 avril 2016
13:30

Technical Briefing for the Launch of Pyramax®

The European Medicines Agency recently granted a positive scientific opinion to Pyramax® granules for infants and children between 5 and 20 kg, as well as a revised label for Pyramax® tablets for adults and children over 20 kg, opening the door to its broader use. Pyramax is the first Artemisinin-based Combination Therapy (ACT) to be reviewed under Article 58, and both presentations are now included in the list of antimalarials pre-qualified by the WHO. This important addition to the armamentarium of ACTs is indicated for the treatment of uncomplicated Plasmodium falciparum and blood-stage Plasmodium vivax malaria.

In the light of this new product label, Shin Poong Pharmaceutical Co. Ltd. and Medicines for Malaria Venture are pleased to invite you to the introduction of Pyramax at a technical briefing that will address the clinical evidence that forms the basis of this positive scientific opinion, the implementation strategy to introduce this drug in malaria-endemic countries, and the medicine’s role in malaria treatment.

Événements sur le même thème